During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering ...

Early data show promising platelet and molecular responses with monoclonal antibody monotherapy in ET and MF, with trials ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

David Spigel, MD, medical oncologist and the chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, discusses the pivotal findings from the AIM-HIGH trial (NCT01817192), ...

An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient characteristics ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS study using HLA-mismatched unrelated donors for peripheral blood and bone ...

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...